PT  - JOURNAL ARTICLE
AU  - Joanna Masel
AU  - Alexandra Shilen
AU  - Bruce Helming
AU  - Jenna Rutschman
AU  - Gary Windham
AU  - Kristen Pogreba-Brown
AU  - Kacey Ernst
TI  - Quantifying meaningful usage of a SARS-CoV-2 exposure notification app on the campus of the University of Arizona
AID  - 10.1101/2021.02.02.21251022
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.02.21251022
4099  - http://medrxiv.org/content/early/2021/10/11/2021.02.02.21251022.short
4100  - http://medrxiv.org/content/early/2021/10/11/2021.02.02.21251022.full
AB  - Objective To measure meaningful, local exposure notification usage without in-app analytics.Methods We surveyed app usage via case investigation interviews at the University of Arizona, with a focus on the period from September 9 to November 28, 2020, after automating the issuance of secure codes to verify positive test results. As independent validation, we compared the number of verification codes issued to the number of local cases.Results Forty six percent (286/628) of infected persons interviewed by university case investigators reported having the app, and 55% (157/286) of these app users shared their positive SARS-CoV-2 test result in the app prior to the case investigation interview, comprising 25% (157/628) of those interviewed. This is corroborated by a 33% (565/1,713) ratio of code issuance (inflated by some unclaimed codes) to cases. Combining the 25% probability that those who test positive rapidly share their test result with a 46% probability that a person they infected can receive exposure notifications, an estimated 11.4% of transmission pairs exhibit meaningful app usage. High usage was achieved without the use of “push” notifications, in the context of a marketing campaign that leveraged social influencers.Conclusions Usage can be assessed, without in-app analytics, within a defined local community such as a college campus rather than an entire jurisdiction. With marketing, high uptake in dense social networks like universities makes exposure notification an impactful complement to traditional contact tracing. Integrating verification code delivery into patient results portals was successful in making the exposure notification process rapid.What is the current understanding of this subject?The extent to which exposure notification technology reduces SARS-CoV-2 transmission depends on usage among infected persons.What does this report add to the literature?A novel metric estimates meaningful usage, and demonstrates potential transmission reduction on a college campus. Clear benefit was seen from simplifying verification of positive test results with automation.What are the implications for public health practice?Defined communities can benefit from local deployment and marketing even in the absence of statewide deployment. Lifting current restrictions on deployment would allow more entities such as campuses to copy the model shown here to be successful.Competing Interest StatementJM consults for WeHealth Solutions PBC (distributors of the Covid Watch Arizona app).Funding StatementFunding was provided by the University of Arizona.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data were collected under public health surveillance guidelines as part of an evaluation of the system. A request for aggregate data was made by the evaluation team to the Pima County Health Department and University of Arizona privacy officers in consultation with the University of Arizona IRB and was deemed not human subjects research. Data on positive tests were publicly available on the University of Arizona dashboard.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAggregate data is available upon request.